rethinkPeptides Search
Menu
Study breakdown

Liraglutide for Type 2 Diabetes: Comprehensive 2011 Clinical Review

evidence
The takeaway

Comprehensive clinical review of liraglutide for T2DM: once-daily injection, superior HbA1c reduction, weight loss, cardiovascular safety signals, and positioning in treatment algorithms.

Key finding

Comprehensive clinical review of liraglutide for T2DM: once-daily injection, superior HbA1c reduction, weight loss, cardiovascular safety signals, and

What the researchers found

Comprehensive clinical review of liraglutide for T2DM: once-daily injection, superior HbA1c reduction, weight loss, cardiovascular safety signals, and positioning in treatment algorithms.

Why it matters

Relevant for peptide research.

How the study worked

research study.

What this study cannot tell us

See abstract.

How to read the evidence

emerging evidence.

When this study was published

Published in 2011.

The bigger picture

Advances peptide research.

Questions still open

  • Further research needed.

Common questions

What was studied?
Liraglutide for Type 2 Diabetes: Comprehensive 2011 Clinical Review
What was found?
Comprehensive clinical review of liraglutide for T2DM: once-daily injection, superior HbA1c reduction, weight loss, cardiovascular safety signals, and positioning in treatment algorithms.

Read the original research

Liraglutide: a review of its use in the management of type 2 diabetes mellitus.

Drugs, 71(17), 2347-73

Citation

Perry, Caroline M. (2011). Liraglutide: a review of its use in the management of type 2 diabetes mellitus.. Drugs, 71(17), 2347-73. https://doi.org/10.2165/11208110-000000000-00000